Maturation inhibitor

A Maturation inhibitor is a class of antiviral drug.

An example is bevirimat.^[1][2]

References

1. ^ Stoddart CA, Joshi P, Sloan B, et al. (2007). "Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice". PLoS ONE 2 (11): e1251. doi:10.1371/journal.pone.0001251. PMID 18043758. PMC: 2080775. http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001251. 
2. ^ Salzwedel K, Martin DE, Sakalian M (2007). "Maturation inhibitors: a new therapeutic class targets the virus structure". AIDS Rev 9 (3): 162–72. PMID 17982941. http://www.aidsreviews.com/resumen.asp?id=970&indice=200793&u=unp. 

v • d • e Antiviral drugs: antiretroviral drugs used against HIV (primarily J05) Entry/fusion inhibitors gp41 (Enfuvirtide) · CCR5 (Maraviroc, Vicriviroc†, PRO 140†) · CD4 (Ibalizumab†) Reverse transcriptase inhibitors (RTIs) Nucleoside & Nucleotide (NRTI) Nucleoside analogues/NARTIs: Abacavir (ABC)°# · Emtricitabine (FTC)°# · Lamivudine (3TC)°# · Didanosine (ddI)# · Zidovudine (AZT)# · Apricitabine† · Stampidine† · Elvucitabine† · Racivir† · Amdoxovir† · Stavudine (d4T)# · Zalcitabine (ddC)◊ Nucleotide analogues/NtRTIs: Tenofovir°# Non-Nucleoside (NNRTI) Efavirenz°# · Nevirapine# · diarylpyrimidines (Etravirine, Rilpivirine†) · Loviride◊ · Delavirdine◊ · Integrase inhibitors Raltegravir · Elvitegravir† · Globoidnan A (experimental) Maturation inhibitors Bevirimat† · Vivecon† Protease Inhibitors (PI) Atazanavir° · Fosamprenavir° · Lopinavir°# · Darunavir · Nelfinavir# · Ritonavir# · Saquinavir# · Tipranavir · Amprenavir◊ · Indinavir◊# Combined formulations Combivir · Atripla · Trizivir · Truvada · Kaletra · Epzicom Experimental agents Uncoating inhibitors TRIM5alpha (gene) Transcription inhibitors Tat antagonists Translation inhibitors Trichosanthin Other Abzyme · Calanolide A · Ceragenin · Cyanovirin-N · Diarylpyrimidines · Epigallocatechin gallate (EGCG) · Foscarnet · Griffithsin · Hydroxyurea · Miltefosine · Portmanteau inhibitors · Seliciclib† · Synergistic enhancers · Tre recombinase · Zinc finger protein transcription factor · KP-1461† Failed agents Dexelvucitabine · Capravirine · Emivirine · Lodenosine · Atevirdine · Brecanavir · Aplaviroc #WHO-EM. †Undergoing clinical trials, not FDA approved. ‡Withdrawn from market. §Development halted. °DHHS preferred first-line agent. ◊Formerly or rarely used agent.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)